Lv3
378 积分 2024-03-06 加入
OP0079 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND-TOCILIZUMAB CONTROLLED PHASE II TRIAL OF VDJ-001, A HIGH-AFFINITY IL-6R ANTAGONIST ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
3天前
已关闭
Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China （2023）: an expert consensus
8天前
已完结
Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society
1个月前
已完结
Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action
1个月前
已完结
Advances in the management of osteoporosis
1个月前
已完结
The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: a post hoc HR-pQCT study
2个月前
已完结
Approach to the Patient - Transitions in Osteoporosis Therapy
2个月前
已完结
Clinical experience with denosumab discontinuation
2个月前
已完结
Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss
2个月前
已完结
Osteoporosis
2个月前
已完结
皖公网安备34019202002308
